Keros is a clinical-stage biopharmaceutical company developing therapeutics that modulate transforming growth factor-beta (TGF-β) signaling to address disorders linked to dysfunctional TGF-β pathways. By leveraging their expertise in TGF-β science, Keros aims to provide disease-modifying treatments for patients with these conditions.
Funding
$140M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Dysfunctional transforming growth factor-beta (TGF-β) signaling pathways are implicated in a range of disorders affecting blood cells and various tissues. Current treatment options often fail to address the underlying cause of these disorders, leaving a significant unmet need for disease-modifying therapies.
Solution
Keros is developing therapeutics that modulate TGF-β signaling to treat disorders linked to dysfunctional TGF-β pathways. By targeting the TGF-β superfamily of regulatory proteins, Keros aims to restore proper signaling and unlock disease-modifying benefits for patients. Their approach focuses on creating novel therapeutics with the ability to precisely modulate TGF-β signaling, potentially leading to improved outcomes for a wide range of patients.
Target Audience
The primary target audience includes patients suffering from disorders linked to dysfunctional TGF-β signaling pathways, as well as the healthcare providers who treat them.
Features
- Focus on modulating the transforming growth factor-beta (TGF-β) superfamily of proteins.
- Development of novel therapeutics designed to address dysfunctional TGF-β pathways.
- Aims to provide disease-modifying treatments for patients with related disorders.